Order O-DSMT Online
Desmetramadol (INN), also known as O-desmethyl tramadol (O-DSMT), is an opioid analgesic and the main active metabolite of tramadol. It is thought that genetic variants of CYP2D6 can cause people to respond differently to tramadol than others.
Desmetramadol (INN), also known as O-desmethyl tramadol (O-DSMT), is an opioid analgesic and the main active metabolite of tramadol. Research has shown that it may be highly effective when used for pain treatment, but this depends on individual metabolism, which varies greatly.
The United States Drug Enforcement Administration references “significant rates of tramadol hydrochloride addiction” and many cases of intentional overdose, with the rate of abuse higher than that of any other prescription opioid (drug), resulting in the Federal Government imposing new controls on the drug in 2014.
O-DSMT is a metabolite of tramadol, and like its active parent compound, it acts as an opioid agonist. It has been reported to have analgesic effects equivalent to tramadol, with only moderate variability as seen with codeine in terms of individual responses and hence limited therapeutic benefits when used to treat moderate pain.
O-Desmethyltramadol is a metabolite of tramadol. It acts as an opioid agonist, and like its active parent compound, it produces analgesic effects equivalent to tramadol.
O-desmethyl tramadol, or O-DSMT, is a metabolite of tramadol. Compared to the parent compound tramadol, it has a stronger affinity for the mu opioid receptors and is more potent as an agonist at these receptors. It has been used in scientific studies as an analgesic. It is of interest to researchers due to its high selectivity for the mu receptors over the delta and kappa opioid receptors.
O-Desmethyltramadol is an opioid analgesic synthesized originally in Germany. While it has not been approved outside of Germany, it is still occasionally used to treat moderate pain, with limited success compared to other more well-known drugs.
ODSMT is a metabolite of tramadol, and its presence in urine has been considered evidence of recent or current tramadol intake.
Desmetramadol (commonly known as O-desmethyl tramadol or O-DSMT) is an active metabolite of the opioid analgesic tramadol, which has been prescribed in many countries for the relief of moderate to severe pain. It is a μ-opioid receptor agonist and around 14 times more potent than tramadol alone.
Desmethyltramadol (or O-DSMT) is a metabolite of tramadol that acts as a centrally active opioid agonist, similar to its parent compound, tramadol. It was first synthesized in 1979 and was one of the first μ-opioid receptor agonists to enter clinical trials; the drug failed because it produced significant side effects like sedation, dizziness and nausea.
Desmethyltramadol is an active metabolite of tramadol, an opioid recently introduced into Phase III trials by a team of researchers in Germany.
The molecule costs less than 10c per mg to manufacture
Methadone deaths fell 10% in the U.S.
O-desmethyl tramadol (O-DSMT) is a metabolite of tramadol. It has similar analgesic effects to tramadol and codeine but is metabolized by an alternate pathway, CYP2D6. Unlike tramadol, O-DSMT remains unbound in the brain and can therefore be psychoactive at higher plasma levels.
O-DSMT is a modified form of tramadol. It undergoes metabolism via the cytochrome P450 enzyme 2D6 to produce the active metabolite M1, which is responsible for most tramadol’s CNS depressant effects and analgesic efficacy .
Back To Shop
